Innovent Biologics (OTCMKTS:IVBXF – Get Free Report) is anticipated to issue its results after the market closes on Tuesday, August 25th. Analysts expect the company to post earnings of $0.0692 per share and revenue of $1.3102 billion for the quarter.
Innovent Biologics Stock Performance
Innovent Biologics stock opened at $11.80 on Friday. Innovent Biologics has a one year low of $9.10 and a one year high of $15.12. The stock’s fifty day moving average price is $11.33 and its two-hundred day moving average price is $10.88.
About Innovent Biologics
Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.
The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).
Read More
- Five stocks we like better than Innovent Biologics
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
